Nuvalent, Inc. - Class A (NUVL) analyst actions
NUVL analyst actions moved a median of -1.44% by the close. Rating and price-target actions on NUVL in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NUVL overview →
12 measured NUVL analyst action events.
Where these NUVL analyst actions landedvs 12 measured NUVL analyst action reactions
| Middle 50% of NUVL analyst action reactions | -1.88% to +1.27% |
|---|---|
| Median reaction (to close) | -1.44% |
| Measured reactions | 12 |
Point-in-time · zero look-ahead
Half of the 12 NUVL analyst action events with a measured close landed between -1.88% and +1.27%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | Press release | -0.24% | -1.64% | |
| Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | -2.31% | -1.79% | |
| Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results | Press release | -1.18% | -5.43% | |
| Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Press release | +0.52% | -5.97% | |
| Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC | Press release | -0.64% | -1.28% | |
| Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results | Press release | +0.51% | +9.50% | |
| Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results | Press release | +1.75% | -1.60% | |
| Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results | Press release | -1.89% | -2.12% | |
| Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Press release | -2.58% | +2.51% | |
| Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results | Press release | +0.18% | +1.37% | |
| Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results | Press release | -0.92% | +1.24% | |
| Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors | Press release | +0.21% | +0.11% |
Keep exploring
More NUVL: earnings → · SEC filings → · NUVL overview →